The CMT Research Foundation, a nonprofit solely focused on delivering treatments and cures for Charcot-Marie-Tooth disease, is pleased to announce that Joseph Mulvey, MBA, PMP, has joined its board of directors. Mr. Mulvey is the founder and president of biopharmaceutical consulting firm Ealaín Technology Solutions (ETS), which provides project management, process design and finance solutions to the biopharma industry. Mr. Mulvey will bring his extensive knowledge and experience in the biopharma arena to help advance research, treatments and cures for CMT.
Among Mr. Mulvey’’s many accomplishments since starting ETS is the successful tech transfer of two major biologics for client CSL Behring, including a therapy to prevent major cardiac events and the first FDA-approved cell-culture-based flu vaccine scalable for pandemic response. He is currently leading the integration and start-up of state-of-the-art process automation across pharmaceutical company Merck and the expansion of its Gardasil®9 (HPV 9-valent, recombinant) vaccine franchise.
“Throughout my career, I have witnessed first-hand the advancement of therapies that were inconceivable less than a generation ago. New discoveries in gene editing offer promise to those living with CMT that this disease will be treatable — if not curable — in their lifetime. I look forward to working with the CMT Research Foundation to help make this promise a reality.”
— Mr. Mulvey
Before founding ETS, Mr. Mulvey served as a process engineer and head of critical systems at Centeon, LLC, where he was involved in the design, installation and start-up of automated biopharma process systems and later the head of power, light, heat and water systems. Mr. Mulvey worked in Ernst & Young’s Life Science practice as part of the advisory team to Searle in advancing its launch of Celebrex® over Merck’s Vioxx®. He also spent seven years as vice president of the Life Science practice of AECOM Corporation, where he developed a global strategic plan, targeting and delivering the doubling of service revenues within three years.
Mr. Mulvey is a dual-degreed engineer across three majors (BioE, Electrical and Computer Engineering) and has an MBA in Finance and Economics from the University of Chicago. Joe served three consecutive terms (six years) on the University of Illinois Alumni Association (UIAA) board of directors and three terms on the alumni board at the Illinois Institute of Technology.
You can connect with Joe Mulvey on LinkedIn.
Meet the CMT Research Foundation Board
The CMT Research Foundation’s board of directors consists of leading experts worldwide who selflessly dedicate their time and talents to deliver treatments and cures for CMT during our lifetime. Get to know these passionate volunteer leaders.
